Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Cadranel

Showing results (191-200 of 329) with videos related to

Pageof 33
Sort By:
Internal and Emergency Medicine|June 23, 2023
Cell and cytokine analyses from bronchoalveolar lavage in non-critical COVID-19 pneumoniaCamille Rolland-Debord, Laurence Piéroni, Farah Bejar, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancerSanjay Popat, Odd Terje Brustugun, Jacques Cadranel, et al.
Journal of Thoracic Disease|September 8, 2022
Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series studyMaxens Decavèle, Antoine Parrot, Michaël Duruisseaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective studyCoralie Fouquet, Martine Antoine, Pascaline Tisserand, et al.
Respiratory Medicine and Research|January 3, 2026
Increased delays of care during the COVID-19 pandemic: experience of a lung cancer rapid diagnostic centerPascal Wang, Anthony Canellas, Floriane Millet, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review studyJacques Cadranel, Keunchil Park, Oscar Arrieta, et al.
Oncotarget|April 19, 2017
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lungRaphaël Saffroy, Vincent Fallet, Nicolas Girard, et al.
Nuclear Medicine Communications|February 11, 2010
Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucoseSona Balogova, Virginie Huchet, Khaldoun Kerrou, et al.
Clinical Lung Cancer|January 26, 2019
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)Michèle Beau-Faller, Matthieu Texier, Hélène Blons, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2012
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trialMichaël Duruisseaux, Laurence Baudrin, Elisabeth Quoix, et al.
Pageof 33

Showing results (191-200 of 329) with videos related to

Sort By:
Pageof 33
Internal and Emergency Medicine|June 23, 2023
Cell and cytokine analyses from bronchoalveolar lavage in non-critical COVID-19 pneumoniaCamille Rolland-Debord, Laurence Piéroni, Farah Bejar, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancerSanjay Popat, Odd Terje Brustugun, Jacques Cadranel, et al.
Journal of Thoracic Disease|September 8, 2022
Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series studyMaxens Decavèle, Antoine Parrot, Michaël Duruisseaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective studyCoralie Fouquet, Martine Antoine, Pascaline Tisserand, et al.
Respiratory Medicine and Research|January 3, 2026
Increased delays of care during the COVID-19 pandemic: experience of a lung cancer rapid diagnostic centerPascal Wang, Anthony Canellas, Floriane Millet, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review studyJacques Cadranel, Keunchil Park, Oscar Arrieta, et al.
Oncotarget|April 19, 2017
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lungRaphaël Saffroy, Vincent Fallet, Nicolas Girard, et al.
Nuclear Medicine Communications|February 11, 2010
Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucoseSona Balogova, Virginie Huchet, Khaldoun Kerrou, et al.
Clinical Lung Cancer|January 26, 2019
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)Michèle Beau-Faller, Matthieu Texier, Hélène Blons, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2012
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trialMichaël Duruisseaux, Laurence Baudrin, Elisabeth Quoix, et al.
Pageof 33